SCHEMBL1407707

SCHEMBL1407707

COc1ccc(-c2c3cccc(F)c3nn2Cc2ccc(F)cc2F)c(C)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 8/20 0.43
NR1H3 Q13133 8/20 0.43
NR1I2 O75469 2/20 0.43
NR3C1 P04150 2/20 0.43
AR P10275 1/20 0.41
RXRA P19793 1/20 0.41
P2RX7 Q99572 1/20 0.40
KCNK3 O14649 1/20 0.40
KDM4E B2RXH2 1/20 0.38
DGAT2 Q96PD7 1/20 0.36
NPC1 O15118 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
KCNH2 Q12809 1/20 0.35
TLR7 Q9NYK1 1/20 0.35
CFTR P13569 2/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1408048 0.91 P2RX7 (0.48) NR1H2NR1H3NR1I2NR3C1P2RX7
SCHEMBL1408297 0.90 NR1H2 (0.43) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1407448 0.88 NR1H2 (0.47) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1408459 0.85 NR1H2 (0.48) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1407200 0.85 NR1H2 (0.45) NR1H2NR1H3P2RX7ALDH1A1PTGDR2
SCHEMBL1408171 0.84 KMT2A (0.48) NR1H2NR1H3KDM4EALDH1A1MAPT
SCHEMBL1407454 0.83 NR1H2 (0.48) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL4034768 0.82 CRHR1 (0.40) P2RX7
SCHEMBL1407447 0.81 NR1H2 (0.47) NR1H2NR1H3NR1I2NR3C1P2RX7
SCHEMBL1407466 0.79 NR1H2 (0.47) NR1H2NR1H3NR1I2NR3C1AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592363-B2 Indazoles WYETH (US) 2009-09-22 US claimed
EP-1773781-A2 INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES Wyeth (US) 2007-04-18 EP claimed
WO-2006017384-A2 INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES WYETH (US) 2006-02-16 WO claimed
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases WYETH (US) 2006-02-09 US claimed
EP-2295429-A1 3-((hetero)aryl)-indazoles as Liver X receptor (LXR) and Th-1 inhibitors for the treatment of cardiovascular diseases Wyeth LLC (US) 2011-03-16 EP disclosed
US-7592363-B2 Indazoles WYETH (US) 2009-09-22 US disclosed
EP-1773781-A2 INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES Wyeth (US) 2007-04-18 EP disclosed
WO-2006017384-A2 INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES WYETH (US) 2006-02-16 WO disclosed
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases WYETH (US) 2006-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases NR1H2, NR1H3, CYP46A1 NR1H2 1/4885NR1H3 2/4885NR1I2 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.